Author:
Zhang Aoli,Liu Lipeng,Zong Suyu,Chen Xiaoyan,Liu Chao,Chang Lixian,Chen Xiaojuan,Yang Wenyu,Guo Ye,Zhang Li,Zou Yao,Chen Yumei,Zhang Yingchi,Ruan Min,Zhu Xiaofan
Abstract
Non-Down’s syndrome acute megakaryocytic leukemia (non-DS-AMKL) is a subtype of childhood acute myeloid leukemia (AML), whose prognosis, prognostic factors and treatment recommendations have not yet to be defined in children. We conducted a retrospective study with 65 newly diagnosed non-DS-AMKL children from August 2003 to June 2020 to investigate the clinical impact of factors and clinical outcome. Among all 65 patients, 47 of them were treated at our center who received three different regimens due to time point of admission (CAMS-another, CAMS-2009 and CAMS-2016 protocol), and the efficacy were compared. Patients with newly diagnosed non-DS-AMKL accounted for 7.4% of pediatric AML cases. The median age of the patients was 18 months at diagnosis, and over 90% of them were under three-years-old. The overall survival (OS) rates were 33.3% ± 1.7%, 66.7% ± 24.4% and 74.2% ± 4.0% for three groups (CAMS-another, CAMS-2009 and CAMS-2016 regimen), respectively. In CAMS-2016 group, the complete remission (CR) rate after induction was 67.7% (21/31), while the total CR rate after all phases of chemotherapy was 80.6% (25/31). The 2-year survival probability did not significantly improve in patients underwent HSCT when compared with non-HSCT group (75.0% ± 4.7% vs. 73.9% ± 4.6%, p=0.680). Those who had a “dry tap” during BM aspiration at admission had significantly worse OS than those without “dry tap” (33.3% ± 8.6% vs. 84.0% ± 3.6%, p=0.006). Moreover, the results also revealed that patients with CD34+ had significantly lower OS (50.0% ± 6.7% vs. 89.5% ± 3.5%, p=0.021), whereas patients with CD36+ had significantly higher OS than those who were negative (85.0% ± 4.0% vs. 54.5% ± 6.6%, p=0.048). In conclusion, intensive chemotherapy resulted in improved prognosis of non-DS-AMKL children and subclassification may base on “dry tap” and immunophenotypic. Although some progress has been made, outcomes of non-DS-AMKL children remain unsatisfactory, especially in HSCT group, when compared with other AML types.
Funder
National Key Research and Development Program of China
Reference40 articles.
1. Über einen fall von akuter megakaryocyblasten-leukemie, zugleich einige bemerkungen zum problem der akuten leukemie;Van Boros;Z Klin Med,1931
2. Megakaryoblastic acute leukemia: identification by the ultrastructural demonstration of platelet peroxidase;Breton-Gorius;Blood,1978
3. Criteria for the diagnosis of acute leukemia of megakaryocyte lineage (M7). a report of the French-American-British cooperative group;Bennett;Ann Internal Med,1985
4. Acute megakaryoblastic leukemia: experience of GIMEMA trials;Pagano;Leukemia,2002
5. Acute megakaryocytic leukemia: the Eastern cooperative oncology group experience;Tallman;Blood,2000
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献